Pioglitazone does not improve insulin signaling in mice with GH over-expression

Journal of Endocrinology

Volumn 219, Issue 2, 2013, Pages 109-117

  Gesing, Adam ^a,b   Bartke, Andrzej ^a   Masternak, Michal M ^c,d  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^d INSTITUTE OF HUMAN GENETICS   (Poland)

Author keywords

Growth hormone; Insulin signaling; Pioglitazone; Transgenic mice

Indexed keywords

ADIPONECTIN; GROWTH HORMONE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; PIOGLITAZONE; PROTEIN KINASE B BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; COW; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACTION; FEMALE; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SIGNALING; MALE; MOUSE; NONHUMAN; PARAMETERS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; STRUCTURAL GENE; WESTERN BLOTTING;

GROWTH HORMONE; INSULIN SIGNALING; PIOGLITAZONE; TRANSGENIC MICE;

ANIMALS; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; GROWTH HORMONE; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84885743494     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0124     Document Type: Article

References (43)

1. Abegunde DO, Mathers CD, Adam T, Ortegon M & Strong K 2007 The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 370 1929-1938. (doi:10.1016/ S0140-6736(07)61696-1)
2. Anisimov VN,Zabezhinski MA,Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV & Blagosklonny MV 2011 Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10 4230-4236. (doi:10.4161/cc.10.24. 18486)
3. Bartke A 2003 Can growth hormone (GH) accelerate aging? Evidence from GH transgenic mice Neuroendocrinology 78 210-216. (doi:10.1159/ 000073704)
4. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A & Partridge L 2010 Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metabolism 11 35-46. (doi:10.1016/j.cmet. 2009.11.010)
5. Coelho M, Oliveira T & Fernandes R 2013 Biochemistry of adipose tissue: an endocrine organ. Archives ofMedical Science 9 191-200. (doi:10.5114/ aoms.2013.33181)
6. Davidson MB 1987 Effect of growth hormone on carbohydrate and lipid metabolism. Endocrine Reviews 8 115-131. (doi:10.1210/edrv-8-2-115)
7. Elte JW & Blickle JF 2007 Thiazolidinediones for the treatment of type 2 diabetes. European Journal of Internal Medicine 18 18-25. (doi:10.1016/ j.ejim.2006.19.007)
8. Fried SK, Bunkin DA & Greenberg AS 1998 Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. Journal of Clinical Endocrinology and Metabolism 83 847-850. (doi:10.1210/jc.83.3.847)
9. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black SC, Brees DJ, Wicks JR et al. 2003 Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBb. Journal of Clinical Investigation 112 197-208. (doi:10.1172/JCI16885)
10. Gesing A, Masternak MM, Wang F, Joseph AM, Leeuwenburgh C, Westbrook R, Lewinski A, Karbownik-Lewinska M & Bartke A 2011 Expression of key regulators of mitochondrial biogenesis in growth hormone receptor knockout (GHRKO) mice is enhanced but is not further improved by other potential life-extending interventions. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences 66 1062-1076. (doi:10.1193/gerona/glr080)
11. Gong Y, Li J, Li C, Mu Y, Xiao Y, Tian H, Pan C & Liu Y 2012 The adipose tissue endocrine mechanism of the prophylactic protective effect of pioglitazone in high-fat diet-induced insulin resistance. Journal of International Medical Research 40 1304-1316. (doi:10.1177/ 147323001204000419)
12. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M & Rizza R 1986 Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. American Journal of Physiology 250 E269-E273.
13. Hers I, Vincent EE & Tavare JM 2011 Akt signalling in health and disease. Cellular Signalling 23 1515-1527. (doi:10.1016/j.cellsig.2011.05.004)
14. Holdaway IM, Rajasoorya RC & Gamble GD 2004 Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 89 667-674. (doi:10.1210/jc.2003-031199)
15. Jamieson E, Chong MM, Steinberg GR, Jovanovska V, Fam BC, Bullen DV, Chen Y, Kemp BE, Proietto J, Kay TW et al. 2005 Socs1 deficiency enhances hepatic insulin signaling. Journal of Biological Chemistry 280 31516-31521. (doi:10.1074/jbc.M502163200)
16. Jiang LQ, Duque-Guimaraes DE, Machado UF, Zierath JR & Krook A 2013 Altered response of skeletal muscle to IL-6 in type 2 diabetic patients. Diabetes 62 355-361. (doi:10.2337/db11-1790)
17. Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T & Kobayashi M 2007 Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 56 795-803. (doi:10.2337/db06-1039)
18. Kim DD, Goh J, Panossian Z, Gamble G, Holdaway I & Grey A 2012 Pioglitazone in acromegaly - an open-label, prospective study. Clinical Endocrinology 77 575-578. (doi:10.1111/j.1365-2265.2012.04411.x)
19. Kopchick JJ, Bellush LL & Coschigano KT 1999 Transgenic models of growth hormone action. Annual Review of Nutrition 19 437-461. (doi:10.1146/annurev.nutr.19.1.437)
20. Krag MB, Nielsen S, Guo Z, Pedersen SB, Schmitz O, Christiansen JS & Jorgensen JO 2008 Peroxisome proliferator-activated receptor g agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. Clinical Endocrinology 69 452-461. (doi:10.1111/ j.1365-2265.2008.03231.x)
21. Krag MB, Rasmussen LM, Hansen TK, Frystyk J, Flyvbjerg A, Moller N & Jorgensen JO 2019 Peroxisome proliferator-activated receptor gamma (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults. Clinical Endocrinology 71 363-368. (doi:10.1111/j.1365-2265.2008.03483.x)
22. Kucia M,Masternak M, Liu R, Shin DM, Ratajczak J, MierzejewskaK, Spong A, Kopchick JJ, Bartke A & Ratajczak MZ 2013 The negative effect of prolonged somatotrophic/insulin signaling on an adult bone marrowresiding population of pluripotent very small embryonic-like stemcells (VSELs). Age 35 315-330. (doi:10.1007/s11357-011-9364-8)
23. Li P, Shibata R, Unno K, Shimano M, Furukawa M, Ohashi T, Cheng X, Nagata K, Ouchi N & Murohara T 2010 Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. Hypertension 55 69-75. (doi:10.1161/HYPERTENSIONAHA.119.141655)
24. Lincoff AM, Wolski K, Nicholls SJ & Nissen SE 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. Journal of the American Medical Association 298 1180-1188. (doi:10.1001/jama.298.10.1180)
25. Mamane Y, Petroulakis E, LeBacquer O & Sonenberg N 2006 mTOR, translation initiation and cancer. Oncogene 25 6416-6422. (doi:10.1038/sj.onc.1219888)
26. McGrane MM, de Vente J, Yun J, Bloom J, Park E, Wynshaw-Boris A, Wagner T, Rottman FM & Hanson RW 1988 Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/ bovine growth hormone gene in transgenic mice. Journal of Biological Chemistry 263 11443-11451.
27. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF et al. 2011 Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences 66 191-201. (doi:10.1193/gerona/glq178)
28. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H et al. 2006 Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. Journal of Biological Chemistry 281 2654-2660. (doi:10.1074/ jbc.M505311200)
29. Pedersen BK & Febbraio MA 2008 Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiological Reviews 88 1379-1406. (doi:10.1152/physrev.90100.2007)
30. Powell LA, Crowe P, Kankara C, McPeake J, McCance DR, Young IS, Trimble ER & McGinty A 2012 Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein b up-regulation. Clinical Science 123 135-146. (doi:10.1042/CS20110662)
31. Puddu A, Sanguineti R, Durante A & Viviani GL 2012 Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regulatory Peptides 177 79-84. (doi:10.1016/j.regpep.2012.05.089)
32. Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, ChanM, Wolka AM, Boardman MK & DURATION-4 Study Group 2012 Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 35 252-258. (doi:10.2337/dc11-1107)
33. Saremi A, Schwenke DC, Buchanan TA, Hodis HN, Mack WJ, Banerji M, Bray GA, Clement SC, Henry RR, Kitabchi AE et al. 2013 Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arteriosclerosis, Thrombosis, and Vascular Biology 33 393-399. (doi:10.1161/ATVBAHA.112.300346)
34. Schaalan MF 2012 Effects of pioglitazone and/or simvastatin on circulating TNFa and adiponectin levels in insulin resistance. Journal of Immunotoxicology 9 201-219. (doi:10.3119/1547691X.2012.661998)
35. Selman C & Partridge L 2012 A double whammy for aging? Rapamycin extends lifespan and inhibits cancer in inbred female mice Cell Cycle 11 17-18. (doi:10.4161/cc.11.1.18736)
36. Slagboom PE, Beekman M, Passtoors WM, Deelen J, Vaarhorst AA, Boer JM, van den Akker EB, van Heemst D, de Craen AJ, Maier AB et al. 2011 Genomics of human longevity. Philosophical Transactions of the Royal Society B: Biological Sciences 366 35-42. (doi:10.1198/rstb.2010.0284)
37. Taniguchi CM, Tran TT, Kondo T, Luo J, Ueki K, Cantley LC & Kahn CR 2006 Phosphoinositide 3-kinase regulatory subunit p85a suppresses insulin action via positive regulation of PTEN. PNAS 103 12193-12197. (doi:10.1073/pnas.0604628103)
38. Ueki K, Kondo T & Kahn CR 2004 Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Molecular and Cellular Biology 24 5434-5446. (doi:10.1128/MCB.24.12.5434-5446.2004)
39. Wan Z, Ritchie I, Beaudoin MS, Castellani L, Chan CB &Wright DC 2012a IL-6 indirectly modulates the induction of glyceroneogenic enzymes in adipose tissue during exercise. PLoS ONE 7 e41719. (doi:10.1371/ journal.pone.0041719)
40. Wan Z, Perry CG, Macdonald T, Chan CB, Holloway GP & Wright DC 2012b IL-6 is not necessary for the regulation of adipose tissue mitochondrial content. PLoS ONE 7 e51233. (doi:10.1371/journal. pone.0051233)
41. Wang Z, Masternak MM, Al-Regaiey KA & Bartke A 2007 Adipocytokines and the regulation of lipid metabolism in growth hormone transgenic and calorie-restricted mice. Endocrinology 148 2845-2853. (doi:10.1210/en.2006-1313)
42. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK et al. 2012 Rapamycin slows aging in mice. Aging Cell 11 675-682. (doi:10.1111/j.1474-9726. 2012.00832.x)
43. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M & Olefsky JM 2002 The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 2968-2974. (doi:10.2337/diabetes.51.10.2968)